{"filing":{"accession_number":"0001628280-26-055962","cik":"0001157601","ticker":"MDGL","company_name":"MADRIGAL PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-11","primary_document":"mdgl-20260811.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026055962/mdgl-20260811.htm"},"events":[{"id":27066,"run_id":24637,"accession_number":"0001628280-26-055962","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"John C. Reed, M.D., Ph.D., a highly accomplished pharmaceutical executive with significant experience at Johnson \u0026 Johnson, Sanofi, and Roche, was appointed to Madrigal's Board of Directors effective August 11, 2026, expanding the Board from eight to nine members. Dr. Reed will serve on the Science and Technology Committee and receive an annual cash retainer of $50,000, committee fee of $10,000, and an equity grant valued at $675,000.","company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28434,"accession_number":"0001628280-26-055962","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of John C. Reed, M.D., Ph.D. to Madrigal's Board of Directors effective August 11, 2026, following Board expansion from eight to nine members. While the disclosure includes compensatory details (annual cash retainer of $50,000, committee fee of $10,000, and an equity grant valued at $675,000), the principal action is the election of a new director to the Board. This is a material governance event for a biopharmaceutical company, particularly given Dr. Reed's prominent background as EVP of R\u0026D at Johnson \u0026 Johnson and his appointment to the Science and Technology Committee.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T12:18:40.248265+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28435,"accession_number":"0001628280-26-055962","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of John C. Reed, M.D., Ph.D., to Madrigal's Board of Directors. Dr. Reed is a highly accomplished executive with significant experience at major pharmaceutical companies (J\u0026J, Sanofi, Roche) and brings deep scientific expertise in drug discovery and R\u0026D strategy. The appointment of a director with this caliber of experience and industry standing is material to investors' assessment of the company's governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T12:18:40.248265+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28434,"accession_number":"0001628280-26-055962","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of John C. Reed, M.D., Ph.D. to Madrigal's Board of Directors effective August 11, 2026, following Board expansion from eight to nine members. While the disclosure includes compensatory details (annual cash retainer of $50,000, committee fee of $10,000, and an equity grant valued at $675,000), the principal action is the election of a new director to the Board. This is a material governance event for a biopharmaceutical company, particularly given Dr. Reed's prominent background as EVP of R\u0026D at Johnson \u0026 Johnson and his appointment to the Science and Technology Committee.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T12:18:40.248265+00:00","company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","filing_date":"2026-08-12"},{"id":28435,"accession_number":"0001628280-26-055962","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of John C. Reed, M.D., Ph.D., to Madrigal's Board of Directors. Dr. Reed is a highly accomplished executive with significant experience at major pharmaceutical companies (J\u0026J, Sanofi, Roche) and brings deep scientific expertise in drug discovery and R\u0026D strategy. The appointment of a director with this caliber of experience and industry standing is material to investors' assessment of the company's governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T12:18:40.248265+00:00","company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","filing_date":"2026-08-12"}]}